NDAORALCAPSULEPriority Review
Approved
Feb 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATROMID-S (clofibrate) is an oral fibrate-class lipid-modifying agent approved in 1967 for the treatment of dyslipidemia and hyperlipidemia. It works by enhancing the clearance of triglyceride-rich lipoproteins and reducing VLDL production. The drug is administered as an oral capsule and represents a legacy therapeutic approach to cholesterol and triglyceride management.
LOE Approaching
Late-stage product approaching loss of exclusivity with minimal growth opportunities; small team focused on maintenance and transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ATROMID-S offers limited career advancement opportunities given the product's approaching loss of exclusivity and minimal linked job count. Positions are primarily defensive and focused on managing decline rather than driving growth or innovation.
Brand Manager (Maintenance)Field Sales Representative
Worked on ATROMID-S at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.